BLOG / 🇺🇸 United States / distress insolvency · · daily

US Corporate Distress Financial Stress SEC Filings — October 30, 2026

USA Corporate Distress & Bankruptcy

By Gunpowder Editorial ·

9 high priority 9 total filings analysed

Executive Summary

A dense cluster of eight listing-standard deficiency notices filed within a single week (Oct 26-30, 2026) signals a broad-based microcap distress wave: five companies (Alset, Actuate, Neumora, Bridger Aerospace, and effectively Banzai) breached the $1.00 minimum bid price rule, while three (Accendra/Owens & Minor, Annovis Bio, Cyngn) face market-cap, equity, or governance-based deficiencies.

The dominant theme is the reverse-stock-split playbook — Alset, Neumora, and Bridger all explicitly flagged splits as cure mechanisms, and Banzai paired its delisting notice with a same-day charter amendment to 850 million authorized shares, a classic recapitalization precursor. Balance-sheet severity varies widely: Annovis disclosed a stockholders' equity deficit of ~$(4.3) million against a $48.4 million market cap (just 3.2% below the $50 million NYSE threshold), whereas Accendra faces the more onerous NYSE 802.01B business-plan process with 18-month cure and quarterly monitoring. Actuate Therapeutics is the standout outlier with two concurrent Nasdaq deficiencies (bid price plus MVLS, the latter due January 11, 2027), creating a compressed dual-deadline risk profile. Notably, no filing disclosed insider buying, dividends, buybacks, or going-concern language — capital allocation is uniformly defensive, with equity issuance/dilution the only lever in play. The April 26, 2027 bid-price cure deadline is now a synchronized catalyst date across at least four names, setting up a Q1 2027 window of split announcements, potential delistings, and forced-selling dynamics.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Distress Financial Stress SEC Filings digest from October 22, 2026.

Investment Signals (10)

  • Alset Inc. ↓ (BEARISH)
    ▲

    Nasdaq $1.00 bid deficiency dated Oct 28, 2026 with a 1-for-5 reverse split already announced and timing 'imminent' — the most advanced cure path in the cohort, but the split implies ~80% price erosion from prior levels

  • Accendra Health (formerly Owens & Minor, ACH) (BEARISH)
    ▲

    NYSE 802.01B notice for failing BOTH the $50M average market cap and $50M stockholders' equity tests — a dual-metric failure on a legacy large-cap healthcare distributor is a structural de-rating signal, not a transient price dip

  • Annovis Bio ↓ (BEARISH)
    ▲

    30-day average market cap of ~$48.4M is only 3.2% below the $50M NYSE threshold, but negative stockholders' equity of ~$(4.3)M as of June 30, 2026 means a market-cap cure alone will not satisfy 802.01B — the equity deficit is the binding constraint

  • Actuate Therapeutics ↓ (BEARISH)
    ▲

    Two simultaneous Nasdaq deficiencies (bid price cure by Apr 26, 2027; MVLS cure by Jan 11, 2027) — the earlier MVLS deadline makes this the most time-compressed delisting risk in the group

  • Banzai International ↓ (BEARISH)
    ▲

    Delisting notice (Item 3.01) filed the same day as a charter amendment expanding authorized shares to 850M (750M Class A, 25M Class B, 75M preferred) — massive authorized-share headroom signals imminent dilutive financing or restructuring, with existing holders facing severe dilution risk

  • Neumora Therapeutics ↓ (BEARISH)
    ▲

    Bid-price notice on the Nasdaq Global Select Market with explicit signaling of a possible reverse split and/or transfer to the Capital Market — the transfer option buys a second 180-day window, extending the timeline but confirming fundamental weakness

  • Bridger Aerospace ↓ (BEARISH)
    ▲

    Deficiency measured over the 30-day period ended Oct 27, 2026, with a clean Apr 26, 2027 cure deadline — a seasonal aerial-firefighting business hitting a bid-price wall outside its revenue season suggests weak off-season liquidity and limited near-term catalysts

  • Cyngn Inc. ↓ (BEARISH)
    ▲

    Audit Committee dropped to two members upon Karen Macleod's resignation (effective at the Nov 3, 2026 annual meeting), breaching Rule 5605(c)(2)(A) — loss of the financially sophisticated chair is a governance red flag that often precedes financial-reporting issues

  • Cohort-wide (BEARISH)
    ▲

    Zero insider purchases, zero buybacks, and zero dividends disclosed across all eight distress filings — management teams are not putting personal capital behind their cure plans, a notable absence of conviction

  • Cohort-wide (BEARISH)
    ▲

    Five of eight notices are pure $1.00 bid-price deficiencies clustered in one week — consistent with a sector-wide microcap liquidity drain rather than company-specific operational failures, implying correlated delisting risk into April 2027

Risk Flags (9)

  • Annovis Bio↓ [HIGH RISK]
    ▼

    Negative stockholders' equity of ~$(4.3)M as of June 30, 2026 combined with a $48.4M market cap — even a modest price recovery leaves the equity test unmet, raising probability of delisting proceedings after the 45-day plan window

  • Actuate Therapeutics↓ [HIGH RISK]
    ▼

    Dual deficiency stack — MVLS compliance deadline Jan 11, 2027 arrives ~3.5 months BEFORE the Apr 26, 2027 bid-price deadline, so failure on MVLS alone could trigger delisting before the bid-price cure period matures

  • Banzai International↓ [HIGH RISK]
    ▼

    Simultaneous delisting notice and 850M authorized-share expansion — the combination of a listing failure and a 17x-plus increase in authorized capital creates acute dilution risk for common holders and suggests a distressed capital raise

  • Accendra Health [HIGH RISK]
    ▼

    NYSE 802.01B requires a business plan within 45 calendar days and 10-business-day notice of intent — missing either deadline triggers immediate delisting proceedings; 18-month cure with quarterly NYSE monitoring is a long, public remediation process

  • Alset Inc.↓ [HIGH RISK]
    ▼

    Reverse split timing 'imminent' but not yet dated — execution risk around the split ratio and post-split price support; a 1-for-5 split implies the stock has traded well below $0.20, and post-split selling pressure from fractional holders is common

  • Neumora Therapeutics↓ [MEDIUM-HIGH RISK]
    ▼

    Reliance on a potential transfer to the Nasdaq Capital Market to extend the cure period signals the company does not expect organic price recovery — a transfer is a delay tactic, not a cure

  • Cyngn Inc.↓ [MEDIUM RISK]
    ▼

    Audit Committee at two members with a cure window stretching to the earlier of the next annual meeting or Nov 3, 2027 — an extended period of non-compliant governance during which any additional director departure would deepen the breach

  • Bridger Aerospace↓ [MEDIUM RISK]
    ▼

    Off-season bid-price failure (30-day period ended Oct 27) with no revenue catalyst until the next fire season — limited fundamental drivers to lift the share price before the Apr 26, 2027 deadline

  • Cohort-wide [MEDIUM RISK]
    ▼

    Synchronized Apr 26, 2027 cure deadlines across Alset, Actuate, Neumora, and Bridger create a Q1 2027 cluster of binary events — index and fund forced-selling could amplify declines as deadlines approach

Opportunities (8)

  • Reverse-Split Arbitrage Screen (OPPORTUNITY)
    ◆

    Alset (1-for-5, imminent), Neumora, and Bridger have all flagged splits — historically, announced splits in sub-$1 names produce short-term volatility spikes; event-driven traders can position around split effective dates for tactical moves

  • Annovis Bio Cure Proximity (OPPORTUNITY)
    ◆

    At ~$48.4M market cap, only a ~3.2% price appreciation is needed to clear the $50M market-cap test — the smallest gap in the cohort, making it the most likely near-term technical cure if the equity deficit can be addressed via a financing

  • Accendra Health Plan Disclosure Catalyst (OPPORTUNITY)
    ◆

    The 45-day business plan submission (due ~Dec 11, 2026) and NYSE acceptance decision is a discrete catalyst — plan acceptance would remove the overhang and could trigger a relief rally in ACH

  • Banzai Restructuring Optionality (OPPORTUNITY)
    ◆

    The 850M authorized-share amendment, while dilutive, provides the currency for a debt-for-equity swap or PIPE — if a credible restructuring is announced, distressed-debt and post-reorg equity investors gain a defined entry point

  • Cyngn Governance Fix is Low-Cost (OPPORTUNITY)
    ◆

    The Audit Committee breach is curable with a single independent director appointment before Nov 3, 2027 — the cheapest and fastest remediation in the cohort, and resolution would remove a governance discount

  • Actuate MVLS Deadline as Binary Event (OPPORTUNITY)
    ◆

    The Jan 11, 2027 MVLS deadline is the earliest hard date in the group — options or event-driven positioning around that date captures the binary outcome 3.5 months ahead of the pack

  • Neumora Capital Market Transfer (OPPORTUNITY)
    ◆

    A transfer to the Nasdaq Capital Market would reset the 180-day clock and provide a second cure window — a procedural catalyst that could temporarily lift the stock on reduced delisting probability

  • Distressed Microcap Basket Short (OPPORTUNITY)
    ◆

    With five bid-price failures in one week and no insider buying across the cohort, a basket short of the weakest names (Banzai, Annovis) into the April 2027 deadlines offers asymmetric downside capture if delistings materialize

Sector Themes (6)

  • Microcap Bid-Price Contagion
    ◆

    5 of 8 distress filings (Alset, Actuate, Neumora, Bridger, and Banzai via delisting notice) are $1.00 minimum-bid failures clustered in a single week — a correlated liquidity drain in sub-$1 equities rather than idiosyncratic operational collapse, implying systemic microcap de-rating

  • The Reverse-Split Playbook
    ◆

    3 of 8 companies (Alset, Neumora, Bridger) explicitly named reverse stock splits as the cure mechanism — the standard microcap response is now near-universal, but splits address the symptom (price) not the cause (market cap, equity, or fundamentals)

  • Zero Capital Returns, Zero Insider Conviction
    ◆

    Across all 8 distress filings, there were no dividends, no buybacks, and no insider purchases disclosed — capital allocation is uniformly defensive, with authorized-share expansion (Banzai to 850M) the only capital action, pointing to dilution as the default funding path

  • NYSE vs Nasdaq Severity Gap
    ◆

    NYSE 802.01B notices (Accendra, Annovis) carry business-plan requirements, 18-month cures, and quarterly monitoring, while Nasdaq bid-price notices offer a cleaner 180-day mechanical cure — NYSE-listed distressed names face longer, more public remediation and greater headline risk

  • Governance Stress Alongside Financial Stress
    ◆

    Cyngn's Audit Committee falling to two members coincides with its listing pressure — governance degradation (loss of financially sophisticated directors) frequently accompanies and can precede financial-reporting deterioration in distressed microcaps

  • Synchronized April 2027 Catalyst Wall
    ◆

    At least 4 companies share an Apr 26, 2027 bid-price cure deadline, while Actuate's MVLS deadline lands Jan 11, 2027 — the Q1 2027 calendar is loaded with binary delisting events, concentrating forced-selling and volatility into a narrow window

Watch List (8)

  • Actuate Therapeutics↓
    👁

    MVLS compliance deadline Jan 11, 2027 — earliest hard date in the cohort; watch for a reverse split or Capital Market transfer announcement before year-end

  • Alset Inc.↓
    👁

    Reverse split timing 'imminent' per the Oct 28 notice — watch for the 8-K announcing the split effective date and ratio within days

  • Accendra Health (ACH)
    👁

    10-business-day NYSE notice of intent (~Nov 10, 2026) and 45-day business plan submission (~Dec 11, 2026) — watch for plan details and any equity raise

  • Banzai International↓
    👁

    Delisting notice plus 850M authorized-share amendment effective Oct 30, 2026 — watch for a dilutive financing, PIPE, or reverse split announcement in the coming weeks

  • Annovis Bio↓
    👁

    45-day compliance plan due ~Dec 13, 2026 — watch whether the plan addresses the $(4.3)M equity deficit, not just the $48.4M market cap gap

  • Cyngn Inc.↓
    👁

    Nov 3, 2026 Annual Meeting — watch for the formal Audit Committee vacancy and any announced replacement director

  • Neumora Therapeutics↓
    👁

    Watch for a Nasdaq Capital Market transfer application or reverse split announcement ahead of the Apr 26, 2027 deadline

  • Bridger Aerospace↓
    👁

    Apr 26, 2027 bid-price deadline with no revenue catalyst until fire season — watch for a reverse split or strategic financing announcement in Q1 2027

Filing Analyses (9)
Alset Inc. 8-K negative materiality 8/10

30-10-2026

Alset Inc. received a Nasdaq notification letter on October 28, 2026, stating it no longer meets the $1.00 minimum bid price requirement under Rule 5550(a)(2) after its closing bid price stayed below $1.00 for 30 consecutive trading days. The notice has no immediate effect on listing; the company has until April 26, 2027 (180 calendar days) to regain compliance, potentially extendable by another 180 days if it meets market value and other initial listing standards. Alset intends to monitor its bid price and has previously announced a planned 1-for-5 reverse stock split, with timing expected to be announced imminently.

  • · Notification received October 28, 2026; 8-K filed October 30, 2026
  • · Deficiency is under Nasdaq Marketplace Rule 5550(a)(2) for The Nasdaq Capital Market
  • · Compliance cure mechanism per Rule 5810(c)(3)(A)
  • · To qualify for the second 180-day period, company must meet market value of publicly held shares and all other initial listing standards except bid price, and provide written notice of intent to cure, potentially via reverse stock split
  • · If Staff determines the company cannot cure, securities would be subject to delisting, with a possible appeal but no assurance of continued listing
  • · Company headquarters: 4800 Montgomery Lane, Suite 210, Bethesda, Maryland 20814
  • · Commission File Number 001-39732; IRS EIN 83-1079861; incorporated in Texas
OWENS & MINOR INC/VA/ 8-K negative materiality 7/10

30-10-2026

Accendra Health, Inc. (formerly Owens & Minor, trading as ACH on NYSE) received a notice from the NYSE on October 27, 2026 that it is not in compliance with Section 802.01B, which requires an average market capitalization of at least $50.0 million over a consecutive 30 trading-day period and stockholders' equity of at least $50.0 million. The notice has no immediate impact on the listing, but the company must notify the NYSE within 10 business days of its intent to submit a business plan and submit that plan within 45 calendar days demonstrating how it will regain compliance within 18 months. The company says the notice does not affect its business operations or SEC reporting obligations.

  • · Company name in filing is Accendra Health, Inc., with common stock trading under symbol ACH on the NYSE
  • · Notice received October 27, 2026; press release issued October 30, 2026
  • · If the NYSE accepts the business plan, the company will be subject to quarterly monitoring by the NYSE of progress against the plan
  • · The notice has no immediate impact on the listing of the common stock, subject to compliance with other NYSE continued listing requirements
  • · Company is incorporated in Virginia, IRS Employer Identification No. 54-1701843, Commission File Number 001-09810
  • · Principal offices located at 4435 Waterfront Drive, Suite 300, Glen Allen, Virginia 23060
Annovis Bio, Inc. 8-K negative materiality 8/10

30-10-2026

Annovis Bio received a NYSE notice on October 29, 2026 that it no longer complies with Section 802.01B continued listing standards, as its 30 trading-day average market capitalization was approximately $48.4 million (below the $50 million threshold) while stockholders' equity was a deficit of approximately $(4.3) million as of June 30, 2026. The company has 45 days to submit a compliance plan and up to 9 months to cure the deficiency; the stock continues trading under 'ANVS' but with a '.BC' indicator denoting below-criteria status. The notice has no immediate impact on operations or SEC reporting obligations, though failure to submit or gain acceptance of the plan would trigger delisting proceedings.

  • · NYSE generally views trading below $0.10 per share as 'abnormally low' and may take accelerated delisting action
  • · NYSE will review the company on a semi-annual basis to confirm compliance with the plan
  • · The '.BC' indicator will be removed once the company regains compliance
  • · The notice does not conflict with or cause an event of default under any material debt or other agreements
  • · Press release dated October 30, 2026 attached as Exhibit 99.1
Cyngn Inc. 8-K negative materiality 5/10

30-10-2026

Cyngn Inc. notified Nasdaq on October 30, 2026 that, upon the resignation of director and Audit Committee Chair Karen Macleod, its Audit Committee will fall to two members, breaching Nasdaq Listing Rule 5605(c)(2)(A) requiring at least three members and one financially sophisticated member. The company expects until the earlier of its next annual meeting or November 3, 2027 to regain compliance and intends to appoint a qualified independent director. Macleod, who notified the company on October 26, 2026 of her decision not to stand for re-election at the November 3, 2026 Annual Meeting, stated her departure was not due to any disagreement with the company.

  • · Cure period runs until the earlier of the next annual meeting of stockholders or November 3, 2027
  • · Macleod's resignation takes effect upon closing of the polls for the election of directors at the November 3, 2026 Annual Meeting
  • · Macleod will continue to serve as director, Audit Committee Chair, and member of the Compensation and Nominating/Corporate Governance Committees until her resignation
  • · The Board intends to fill the resulting vacancy
  • · Company is an emerging growth company incorporated in Delaware, file number 001-40932
Banzai International, Inc. 8-K negative materiality 8/10

30-10-2026

Banzai International filed an 8-K on October 30, 2026 disclosing a delisting notice (Item 3.01) and a same-day Certificate of Amendment increasing authorized capital to 850,000,000 shares, comprising 750,000,000 Class A common, 25,000,000 Class B common, and 75,000,000 preferred shares, all at $0.0001 par value. The charter amendment, approved by the requisite stockholders and signed by CEO Joseph Davy, took effect at 12:01 a.m. Eastern on October 30, 2026. The simultaneous delisting notice signals a negative listing-status development, while the capital increase may support restructuring or financing efforts.

  • · Amendment adopted pursuant to Section 242 of the Delaware General Corporation Law
  • · Amendment effective at 12:01 a.m. Eastern Time on October 30, 2026
  • · Requisite stockholders approved the amendment
  • · Filing includes Items 3.01 (delisting notice), 5.03 (charter amendment), 5.07 (stockholder vote), and 9.01 (exhibits)
ACTUATE THERAPEUTICS, INC. 8-K negative materiality 7/10

30-10-2026

Actuate Therapeutics received a Nasdaq written notice on October 28, 2026, stating its common stock closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1). The notice has no immediate effect on listing, and the company has a 180-day compliance period until April 26, 2027 to regain compliance by maintaining a $1.00+ closing bid for at least 10 consecutive business days. This adds to a separate previously disclosed MVLS deficiency notice received July 15, 2026 (compliance deadline January 11, 2027), meaning the company faces two concurrent Nasdaq listing deficiencies with no assurance of cure.

  • · Notice received October 28, 2026; 8-K filed October 30, 2026.
  • · Common Stock par value is $0.000001 per share, trading on Nasdaq Global Market under symbol ACTU.
  • · Separate MVLS deficiency notice received July 15, 2026, with compliance deadline of January 11, 2027.
  • · Bid price notice does not affect the MVLS compliance period.
  • · Second 180-day period requires meeting Nasdaq Capital Market market value of publicly-held shares and other initial listing standards (except bid price).
  • · Company is an emerging growth company incorporated in Delaware, CIK 0001652935, file number 001-42139.
  • · Failure to regain compliance across allotted periods could result in delisting.
Neumora Therapeutics, Inc. 8-K negative materiality 7/10

30-10-2026

Neumora Therapeutics (NMRA) received a written notice from Nasdaq on October 26, 2026, indicating it is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market under Listing Rule 5450(a)(1). The company has 180 calendar days, until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days; it may seek additional time by transferring to the Nasdaq Capital Market, and has signaled it may pursue a reverse stock split. There is no assurance compliance will be regained, and failure could result in delisting, subject to appeal.

  • · Notice received October 26, 2026; 8-K filed October 30, 2026
  • · Compliance deadline is April 26, 2027 (180 calendar days)
  • · To cure, closing bid must be at least $1.00 for a minimum of ten consecutive business days
  • · If not compliant by April 26, 2027, company may apply to transfer to Nasdaq Capital Market, requiring market value of publicly held shares and other initial listing standards plus an application fee
  • · Company would be entitled to appeal any delisting determination, but no assurance Nasdaq would grant continued listing
  • · Company is considering a reverse stock split among options to resolve noncompliance
Bridger Aerospace Group Holdings, Inc. 8-K negative materiality 7/10

30-10-2026

Bridger Aerospace Group Holdings, Inc. (Nasdaq: BAER) received a Nasdaq deficiency letter on October 28, 2026, notifying the company that its common stock failed to maintain the $1.00 minimum bid price over the 30 consecutive business day period ended October 27, 2026, in violation of Nasdaq Listing Rule 5450(a)(1). The letter has no immediate effect on listing, and the company has until April 26, 2027 to regain compliance by achieving a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company said it will monitor its bid price and may consider options including a reverse stock split, but cautioned there can be no assurance it will regain compliance.

  • · Deficiency letter dated October 28, 2026, based on closing bid price for the 30 consecutive business day period ended October 27, 2026
  • · Compliance deadline is April 26, 2027 (Nasdaq Listing Rule 5810(c)(3)(A))
  • · If compliance is not regained, Staff will issue written delisting notice; company may appeal to a Nasdaq Hearings Panel, though no assurance of success
  • · Common Stock continues to trade on The Nasdaq Global Market under symbol BAER with no immediate effect on listing
  • · Company is an emerging growth company per the filing checkbox
  • · Commission File Number 001-41603; IRS EIN 88-3599336; incorporated in Delaware; headquarters at 90 Aviation Lane, Belgrade, MT 59714
Game Your Game Inc. 8-K neutral materiality 4/10

30-10-2026

Game Your Game Inc. filed an 8-K on October 30, 2026 disclosing the appointment of Veronica V. Montenegro to its Board of Directors effective October 28, 2026, with service through the 2027 annual stockholders' meeting. She will receive $50,000 annual cash compensation plus $27,500 in aggregate committee fees (Audit, Compensation, and as Governance Committee chair) and annual stock option grants with a grant date fair value of $77,500, fully vested with a 10-year term. The filing's header carries a delisting/failure-to-satisfy listing standard item flag, but the substantive body covers only the director appointment and related exhibits, with no financial results or delisting specifics disclosed.

  • · Director term runs through the date of the next annual stockholders' meeting in 2027, with annual re-election thereafter
  • · Stock options are fully vested on grant date, have a 10-year term, and exercise price equals fair market value on grant date
  • · Cash and option compensation payable/issued in quarterly installments in arrears, prorated for the initial partial quarter
  • · No arrangements or understandings between Ms. Montenegro and any other person regarding her selection; no family relationships or Item 404(a) related-party transactions
  • · Company incorporated in Delaware (state of incorporation DE) though indemnification references Nevada law; fiscal year end December 31
  • · Exhibits include Offer Letter dated October 28, 2026 (Ex 10.1), Form of Indemnification Agreement (Ex 10.2), and Form of 2026 Equity Incentive Plan Stock Option Agreement (Ex 10.3)
  • · Filing signed by CEO Soumya Das on October 30, 2026; SEC File No. 001-43419

Get daily alerts with 10 investment signals, 9 risk alerts, 8 opportunities and full AI analysis of all 9 filings

Start free trial Browse all digests

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Distress Financial Stress SEC Filings

October 21, 2026

US Corporate Distress Financial Stress SEC Filings — October 21, 2026

October 20, 2026

US Corporate Distress Financial Stress SEC Filings — October 20, 2026

October 19, 2026

US Corporate Distress Financial Stress SEC Filings — October 19, 2026

October 16, 2026

US Corporate Distress Financial Stress SEC Filings — October 16, 2026

🇺🇸 More from United States

View all →

October 23, 2026

US Pre-Market SEC Filings Roundup — October 23, 2026

US Pre-Market SEC Filings Roundup

October 23, 2026

US Merger & Acquisition SEC Filings — October 23, 2026

US Merger & Acquisition SEC Filings

October 23, 2026

USA Insider Trading Pulse — October 23, 2026

USA Insider Trading Pulse

October 23, 2026

US Corporate Board Director Changes SEC Filings — October 23, 2026

US Corporate Board Director Changes SEC Filings
← All United States digests